Augmentation of PPARγ-TAZ interaction contributes to the anti-adipogenic activity of KR62980

Hana Jung, Mi Sook Lee, Eun Jung Jang, Jin Hee Ahn, Nam Sook Kang, Sung Eun Yoo, Myung Ae Bae, Jeong-Ho Hong, Eun Sook Hwang

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor that plays a pivotal role in the modulation of gene expression involved in adipocyte differentiation and insulin sensitivity. It has been previously established that thiazolidinedione (TZD) PPARγ ligands such as rosiglitazone have potent anti-diabetic and adipogenic activities. A novel non-TZD ligand for PPARγ, KR62980 has recently been characterized to increase insulin sensitivity and to be weakly adipogenic in 3T3-L1 cells or anti-adipogenic in rosiglitazone-induced adipocyte differentiation. In this study, we have confirmed that KR62980 substantially suppresses rosiglitazone-induced adipocyte differentiation and attenuates adipogenic gene expression via an induced reduction in PPARγ activity. KR62980 increased the nuclear localization of TAZ, a PPARγ suppressor, and also enhanced the interaction between PPARγ and TAZ, thus resulting in the TAZ-mediated suppression of PPARγ activity. Furthermore, KR62980 failed to suppress PPARγ-mediated adipogenic gene expression and adipocyte differentiation in TAZ knockdown 3T3-L1 cells, thus indicating a TAZ-dependent suppressive activity of KR62980 on PPARγ-mediated function. These findings strongly suggest that the novel PPARγ ligand, KR62980, may prove to be beneficial to anti-adipogenic function through the suppression of PPARγ-mediated adipocyte differentiation by activating TAZ.

Original languageEnglish
Pages (from-to)1323-1329
Number of pages7
JournalBiochemical Pharmacology
Volume78
Issue number10
DOIs
Publication statusPublished - 2009 Nov 15

Fingerprint

Peroxisome Proliferator-Activated Receptors
rosiglitazone
Adipocytes
Gene expression
3T3-L1 Cells
Ligands
Gene Expression
Insulin Resistance
1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester
Insulin
Transcription Factors
Modulation

Keywords

  • Adipocyte differentiation
  • KR62980
  • PPARγ
  • Rosiglitazone
  • TAZ

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Jung, H., Lee, M. S., Jang, E. J., Ahn, J. H., Kang, N. S., Yoo, S. E., ... Hwang, E. S. (2009). Augmentation of PPARγ-TAZ interaction contributes to the anti-adipogenic activity of KR62980. Biochemical Pharmacology, 78(10), 1323-1329. https://doi.org/10.1016/j.bcp.2009.07.001

Augmentation of PPARγ-TAZ interaction contributes to the anti-adipogenic activity of KR62980. / Jung, Hana; Lee, Mi Sook; Jang, Eun Jung; Ahn, Jin Hee; Kang, Nam Sook; Yoo, Sung Eun; Bae, Myung Ae; Hong, Jeong-Ho; Hwang, Eun Sook.

In: Biochemical Pharmacology, Vol. 78, No. 10, 15.11.2009, p. 1323-1329.

Research output: Contribution to journalArticle

Jung, H, Lee, MS, Jang, EJ, Ahn, JH, Kang, NS, Yoo, SE, Bae, MA, Hong, J-H & Hwang, ES 2009, 'Augmentation of PPARγ-TAZ interaction contributes to the anti-adipogenic activity of KR62980', Biochemical Pharmacology, vol. 78, no. 10, pp. 1323-1329. https://doi.org/10.1016/j.bcp.2009.07.001
Jung, Hana ; Lee, Mi Sook ; Jang, Eun Jung ; Ahn, Jin Hee ; Kang, Nam Sook ; Yoo, Sung Eun ; Bae, Myung Ae ; Hong, Jeong-Ho ; Hwang, Eun Sook. / Augmentation of PPARγ-TAZ interaction contributes to the anti-adipogenic activity of KR62980. In: Biochemical Pharmacology. 2009 ; Vol. 78, No. 10. pp. 1323-1329.
@article{6d972697ffad40b08908b4c292da1f24,
title = "Augmentation of PPARγ-TAZ interaction contributes to the anti-adipogenic activity of KR62980",
abstract = "Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor that plays a pivotal role in the modulation of gene expression involved in adipocyte differentiation and insulin sensitivity. It has been previously established that thiazolidinedione (TZD) PPARγ ligands such as rosiglitazone have potent anti-diabetic and adipogenic activities. A novel non-TZD ligand for PPARγ, KR62980 has recently been characterized to increase insulin sensitivity and to be weakly adipogenic in 3T3-L1 cells or anti-adipogenic in rosiglitazone-induced adipocyte differentiation. In this study, we have confirmed that KR62980 substantially suppresses rosiglitazone-induced adipocyte differentiation and attenuates adipogenic gene expression via an induced reduction in PPARγ activity. KR62980 increased the nuclear localization of TAZ, a PPARγ suppressor, and also enhanced the interaction between PPARγ and TAZ, thus resulting in the TAZ-mediated suppression of PPARγ activity. Furthermore, KR62980 failed to suppress PPARγ-mediated adipogenic gene expression and adipocyte differentiation in TAZ knockdown 3T3-L1 cells, thus indicating a TAZ-dependent suppressive activity of KR62980 on PPARγ-mediated function. These findings strongly suggest that the novel PPARγ ligand, KR62980, may prove to be beneficial to anti-adipogenic function through the suppression of PPARγ-mediated adipocyte differentiation by activating TAZ.",
keywords = "Adipocyte differentiation, KR62980, PPARγ, Rosiglitazone, TAZ",
author = "Hana Jung and Lee, {Mi Sook} and Jang, {Eun Jung} and Ahn, {Jin Hee} and Kang, {Nam Sook} and Yoo, {Sung Eun} and Bae, {Myung Ae} and Jeong-Ho Hong and Hwang, {Eun Sook}",
year = "2009",
month = "11",
day = "15",
doi = "10.1016/j.bcp.2009.07.001",
language = "English",
volume = "78",
pages = "1323--1329",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Augmentation of PPARγ-TAZ interaction contributes to the anti-adipogenic activity of KR62980

AU - Jung, Hana

AU - Lee, Mi Sook

AU - Jang, Eun Jung

AU - Ahn, Jin Hee

AU - Kang, Nam Sook

AU - Yoo, Sung Eun

AU - Bae, Myung Ae

AU - Hong, Jeong-Ho

AU - Hwang, Eun Sook

PY - 2009/11/15

Y1 - 2009/11/15

N2 - Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor that plays a pivotal role in the modulation of gene expression involved in adipocyte differentiation and insulin sensitivity. It has been previously established that thiazolidinedione (TZD) PPARγ ligands such as rosiglitazone have potent anti-diabetic and adipogenic activities. A novel non-TZD ligand for PPARγ, KR62980 has recently been characterized to increase insulin sensitivity and to be weakly adipogenic in 3T3-L1 cells or anti-adipogenic in rosiglitazone-induced adipocyte differentiation. In this study, we have confirmed that KR62980 substantially suppresses rosiglitazone-induced adipocyte differentiation and attenuates adipogenic gene expression via an induced reduction in PPARγ activity. KR62980 increased the nuclear localization of TAZ, a PPARγ suppressor, and also enhanced the interaction between PPARγ and TAZ, thus resulting in the TAZ-mediated suppression of PPARγ activity. Furthermore, KR62980 failed to suppress PPARγ-mediated adipogenic gene expression and adipocyte differentiation in TAZ knockdown 3T3-L1 cells, thus indicating a TAZ-dependent suppressive activity of KR62980 on PPARγ-mediated function. These findings strongly suggest that the novel PPARγ ligand, KR62980, may prove to be beneficial to anti-adipogenic function through the suppression of PPARγ-mediated adipocyte differentiation by activating TAZ.

AB - Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor that plays a pivotal role in the modulation of gene expression involved in adipocyte differentiation and insulin sensitivity. It has been previously established that thiazolidinedione (TZD) PPARγ ligands such as rosiglitazone have potent anti-diabetic and adipogenic activities. A novel non-TZD ligand for PPARγ, KR62980 has recently been characterized to increase insulin sensitivity and to be weakly adipogenic in 3T3-L1 cells or anti-adipogenic in rosiglitazone-induced adipocyte differentiation. In this study, we have confirmed that KR62980 substantially suppresses rosiglitazone-induced adipocyte differentiation and attenuates adipogenic gene expression via an induced reduction in PPARγ activity. KR62980 increased the nuclear localization of TAZ, a PPARγ suppressor, and also enhanced the interaction between PPARγ and TAZ, thus resulting in the TAZ-mediated suppression of PPARγ activity. Furthermore, KR62980 failed to suppress PPARγ-mediated adipogenic gene expression and adipocyte differentiation in TAZ knockdown 3T3-L1 cells, thus indicating a TAZ-dependent suppressive activity of KR62980 on PPARγ-mediated function. These findings strongly suggest that the novel PPARγ ligand, KR62980, may prove to be beneficial to anti-adipogenic function through the suppression of PPARγ-mediated adipocyte differentiation by activating TAZ.

KW - Adipocyte differentiation

KW - KR62980

KW - PPARγ

KW - Rosiglitazone

KW - TAZ

UR - http://www.scopus.com/inward/record.url?scp=70349445397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349445397&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2009.07.001

DO - 10.1016/j.bcp.2009.07.001

M3 - Article

C2 - 19591806

AN - SCOPUS:70349445397

VL - 78

SP - 1323

EP - 1329

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 10

ER -